Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 13/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.48 |
| ▸ | CCND1 | P24385 | 13/20 | 0.48 |
| ▸ | CDK2 | P24941 | 13/20 | 0.48 |
| ▸ | CCND3 | P30281 | 13/20 | 0.48 |
| ▸ | JAK2 | O60674 | 7/20 | 0.47 |
| ▸ | JAK1 | P23458 | 7/20 | 0.47 |
| ▸ | TYK2 | P29597 | 7/20 | 0.47 |
| ▸ | JAK3 | P52333 | 7/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536918 | 0.86 | FGFR1 (0.37) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL6583189 | 0.84 | PDPK1 (0.44) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL15868927 | 0.80 | FGFR1 (0.45) | CDK2FGFR1FLT1 | |
| SCHEMBL3540417 | 0.79 | CDK2 (0.52) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL3535364 | 0.79 | FLT3 (0.42) | KDRFGFR1FLT1 | |
| SCHEMBL3542676 | 0.77 | FGFR1 (0.48) | CDK2JAK2TYK2JAK3CHEK1 | |
| SCHEMBL3537078 | 0.77 | FGFR1 (0.43) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL3539176 | 0.77 | CDK4 (0.42) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL3535767 | 0.76 | FGFR1 (0.43) | CDK4CCNA2CCND1CDK2CCND3 | |
| SCHEMBL3532400 | 0.75 | FGFR1 (0.54) | CDK2JAK2TYK2JAK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | CDK4 646/4885CCNA2 3156/4885CCND1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.